Radiation therapy with or without concurrent low-dose daily chemotherapy in locally advanced, nonmetastatic squamous cell carcinoma of the head and neck

Journal of Clinical Oncology

Volumn 22, Issue 17, 2004, Pages 3540-3548

  Jeremic, Branislav ^a   Milicic, Biljana ^a   Dagovic, Aleksandar ^a   Vaskovic, Zeljko ^a   Tadic, Ljiljana ^a  

^a University Hospital   (Serbia)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; ANTINEOPLASTIC AGENT;

ACUTE TOXICITY; ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; HEAD AND NECK CARCINOMA; HUMAN; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; XEROSTOMIA; ADJUVANT CHEMOTHERAPY; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; FEMALE; HEAD AND NECK TUMOR; MALE; METASTASIS; METHODOLOGY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; RADIATION DOSE FRACTIONATION; RADIOTHERAPY; RETROSPECTIVE STUDY; SURVIVAL RATE;

ANTINEOPLASTIC AGENTS; CARBOPLATIN; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; CISPLATIN; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DOSE FRACTIONATION; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; RADIOTHERAPY; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 4444312852     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.10.076     Document Type: Article

References (57)

1. Million RR, Cassisi NJ: Management of Head and Neck Cancer. A Multidisciplinary Approach. Philadelphia, PA, JB Lippincott, 1994
2. Wang CC, Blitzer PH, Suit HD: Twice-a-day radiation therapy for cancer of the head and neck. Cancer 55:2100-2104, 1985
3. Cox JD, Pajak TF, Marcial VA, et al: Dose-response for local control with hyperfractionated radiation therapy in advanced carcinomas of the upper aerodigestive tracts: Preliminary report of Radiation Therapy Oncology Group protocol 83-13. Int J Radiat Oncol Biol Phys 18:515-521, 1990
4. Ang KK, Peters LJ, Weber RS, et al: Concomitant boost radiotherapy schedule in the treatment of carcinoma of the oropharynx and nasopharynx. Int J Radiat Oncol Biol Phys 19:1339-1345, 1990
5. Dische S, Saunders M, Barrett A, et al: A randomized multicentre trial of CHART versus conventional radiotherapy in head and neck. Radiother Oncol 44:123-136, 1997
6. Al-Sarraf M, Pajak TF, Marcial VA, et al: Concurrent radiotherapy and chemotherapy with cisplatin in inoperable squamous cell carcinoma of the head and neck. An RTOG study. Cancer 59:259-265, 1987
7. Tobias JS, Smith BJ, Blackman G, et al: Concurrent daily cisplatin and radiotherapy in locally advanced squamous carcinoma of the head and neck and bronchus. Radiother Oncol 9:263-268, 1987
8. Browman GP, Cripps C, Hodson DI, et al: Placebo-controlled randomized trial of infusional fluorouracil during standard radiotherapy in locally advanced head and neck cancer. J Clin Oncol 12:2648-2653, 1994
9. Jeremic B, Shibamoto Y, Stanisavljevic B, et al: Radiation therapy alone or with concurrent low-dose daily either cisplatin or carboplatin in locally advanced unresectable squamous cell carcinoma of the head and neck: A prospective randomized trial. Radiother Oncol 43:29-37, 1997
10. Jeremic B, Shibamoto Y, Milicic B, et al: Hyperfractionated radiation therapy with or without concurrent low-dose cisplatin in locally advanced squamous cell carcinoma of the head and neck: A prospective randomized trial. J Clin Oncol 18:1458-1464, 2000
11. Wendt TG, Grabenbauer GG, Rodel CM, et al: Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: A randomized multicenter study. J Clin Oncol 16:1318-1324, 1998
12. Brizel DM, Albers ME, Fisher SR, et al: Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 338:1798-1804, 1998
13. Huguenin P, Glanzmann C, Taussky D, et al: Hyperfractionated radiotherapy and simultaneous cisplatin for stage-III and -IV carcinomas of the head and neck. Long-term results including functional outcome. Strahlenther Onkol 174:397-402, 1998
14. Chao KS, Deasy JO, Markman J, et al: A prospective study of salivary function sparing in patients with head-and-neck cancers receiving intensity- modulated or three-dimensional radiation therapy: Initial results. Int J Radiat Oncol Biol Phys 49:907-916, 2001
15. Claus F, Duthoy W, Bothenberg T, et al: Intensity modulated radiation therapy for oropharyngeal and oral cavity tumors: Clinical use and experience. Oral Oncol 38:597-604, 2002
16. Rosenthal DI, Lee JH, Sinard R, et al: Phase I study of paclitaxel given by seven-week continuous infusion concurrent with radiation therapy for locally advanced squamous cell carcinoma of the head and neck. J Clin Oncol 19:1363-1373, 2001
17. Sanchiz F, Milla A, Torner J, et al: Single fraction per day versus two fractions per day versus radiochemotherapy in the treatment of head and neck cancer. Int J Radiat Oncol Biol Phys 19:1347-1350, 1990
18. Pinto LHJ, Canary PCV, Araujo CM, et al: Prospective randomized trial comparing hyperfractionated versus conventional radiotherapy in stages III and IV oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys 21:557-562, 1991
19. Horiot JC, LeFur R, N'Guyen T, et al: Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: Final analysis of a randomized trial of the EORTC cooperative group of radiotherapy. Radiother Oncol 25:231-241, 1992
20. Lewin F, Damber L, Jonsson H, et al: Neoadjuvant chemotherapy with cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the head and neck: A randomized phase III study. Radiother Oncol 43:23-28, 1997
21. Domenge C, Lancar R, Coche-Deqeuan B, et al: Induction chemotherapy before radiotherapy in oropharyngeal carcinoma: A randomized trial. Eur J Cancer 31:S86, 1995 (suppl 5)
22. Jaulerry C, Rodriguez J, Brunin F, et al: Induction chemotherapy in advanced head and neck tumors: Results of two randomized trials. Int J Radiat Oncol Biol Phys 23:483-489, 1992
23. Vermund H, Kaalhus O, Winther F, et al: Bleomycin and radiation therapy in squamous cell carcinoma of the upper aero-digestive tract: A phase III clinical trial. Int J Radiat Oncol Biol Phys 11:1877-1886, 1985
24. Weissberg JB, Son YH, Papac RJ, et al: Randomized clinical trial of mitomycin C as an adjunct to radiotherapy in head and neck cancer. Int J Radiat Oncol Biol Phys 17:3-9, 1989
25. Keane TJ, Cummings BJ, O'Sullivan B, et al: A randomized trial of radiation therapy compared to split course radiation therapy combined with mitomycin C and 5-fluorouracil as initial treatment for advanced laryngeal and hypopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 25:613-618, 1993
26. Taylor SG, Murthy AK, Vannetzel JM, et al: Randomized comparison of neoadjuvant cisplatin and fluorouracil infusion followed by radiation versus concomitant treatment in advanced head and neck cancer. J Clin Oncol 12:385-395, 1994
27. Paccagnella A, Orlando A, Marchiori C, et al: Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: A study by the Grupo di Studio sui Tumori della Testa a del Collo. J Natl Cancer Inst 86:265-272, 1994
28. El Sayed S, Nelson N: Adjuvant and adjunctive chemotherapy in the management of squamous cell carcinoma of the head and neck region. A meta-analysis of prospective and randomized trials. J Clin Oncol 14:838-847, 1996
29. Browman GP, Hodson DI, Mackenzie RJ, et al: Choosing a concomitant chemotherapy and radiotherapy regimen for squamous cell head and neck cancer: A systematic review of the published literature with subgroup analysis. Head Neck 23:579-589, 2001
30. Munro AJ: An overview of randomized controlled trials of adjuvant chemotherapy in head and neck cancer. Br J Cancer 71:83-91, 1995
31. Pignon JP, Bourhis J, Domenge C, et al: Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three meta-analyses of updated individual data. Lancet 355:949-955, 2000
32. Withers HR: Biologic basis for altered fractionated schemes. Cancer 55:2086-2095, 1985
33. Withers HR: Inherent acceleration of tumor dose-rate in hyperfractionated regimens. Int J Radiat Oncol Biol Phys 14:400, 1988
34. Withers HR, Peters LJ: Biological aspects of radiation therapy, in Fletcher GH (ed): Textbook of Radiotherapy (ed 3). Philadelphia, PA, Lea and Febiger, 1980, p 103
35. Jeremic B, Shibamoto Y, Acimovic L, et al: Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer. J Clin Oncol 13:452-458, 1995
36. Jeremic B, Shibamoto Y, Acimovic L, et al: Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: A randomized study. J Clin Oncol 14:1065-1070, 1996
37. Jeremic B, Shibamoto Y, Milicic B, et al: Concurrent radiochemotherapy for patients with stage III non-small-cell lung cancer (NSCLC). Long-term results of a phase II study. Int J Radiat Oncol Biol Phys 42:1091-1096, 1998
38. Jeremic B, Shibamoto Y, Acimovic L, et al: Hyperfractionated radiation therapy and concurrent low-dose, daily carboplatin/etoposide with or without week-end carboplatin/etoposide chemotherapy in stage III non-small-cell lung cancer: A randomized trial. Int J Radiat Oncol Biol Phys 50:19-25, 2001
39. Jeremic B, Shibamoto Y, Acimovic L, et al: Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small cell lung cancer. J Clin Oncol 15:893-900, 1997
40. Jeremic B, Shibamoto Y, Nikolic N, et al: The role of radiation therapy in the combined modality treatment of patients with extensive disease small-cell lung cancer (ED SCLC): A randomized study. J Clin Oncol 17:2092-2099, 1999
41. Cox JD, Stetz JA, Pajak TF: Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for the Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31:1341-1346, 1995
42. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47:207-214, 1981
43. Fu KK, Pajak TF, Trotti A, et al: A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: First report of RTOG 9003. Int J Radiat Oncol Biol Phys 48:7-16, 2000
44. Horiot J-C, Bontemps P. van der Bogaert W, et al: Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: Results of the EORTC 22851 randomized trial. Radiother Oncol 44:111-121, 1997
45. Cox JD, Pajak TF, Marcial VA, et al: ASTRO prenary: Interfraction interval is a major determinant of late effects, with hyperfractionated radiation therapy of carcinomas of upper respiratory and digestive tracts: Results from Radiation Therapy Oncology Group protocol 8313. Int J Radiat Oncol Biol Phys 20:1191-1195, 1991
46. Withers HR, Peters LJ: Transmutability of dose and time. Commentary on the first report of RTOG 90003 (K. K. Fu et al.). Int J Radiat Oncol Biol Phys 48:1-2, 2000
47. Cox JD, Pajak TF, Marcial VA, et al: Interruptions adversely affect local control and survival with hyperfractionated radiation therapy of carcinomas of the respiratory/digestive tracts: New evidence for accelerated proliferation from RTOG Protocol 83-13. Cancer 69:2744-2748, 1992
48. Withers HR, Taylor JMG, Maciejewski B: The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol 27:131-146, 1988
49. Fowler JF, Lindstrom MJ: Loss of local control with prolongation in radiotherapy. Int J Radiat Oncol Biol Phys 23:457-467, 1992
50. Hendry JH, Bentzen SM, Dale RG, et al: A modelled comparison of the effects of using different ways to compensate for missed treatment days in radiotherapy. Clin Oncol (R Coll Radiol) 8:297-307, 1996
51. Budach VG, Geismar D, Lammert I, et al Accelerated hyperfractionated radiation therapy to 70.6 Gy plus 5-FU/MMC (C-HART) is more effective than HART to 77.6 Gy alone for locally advanced head and neck cancer. Four-year results of the German ARO 95-6 trial in 384 patients. Proc Am Soc Ther Radiol Oncol 54:5153-5154 2003 (abstr 49)
52. Overgaard J, Sand Hansen H, Grau C, et al: The DAHANCA 6 & 7 trial. A randomized multicenter study of 5 versus 6 fractions per week of conventional radiotherapy of squamous cell carcinoma of the head and neck. Radiother Oncol 56:564, 2000 (suppl 1. abstr)
53. Adelstein DJ, Sexton JP, Lavertu P, et al: A phase III randomized trial comparing concurrent radiotherapy alone in resectable stage III and IV squamous cell head and neck cancer: Preliminary results. Head Neck 19:567-575, 1997
54. Calais G, Alfonsi M, Bardet E, et al: Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst 91:2081-2086, 1999
55. Brizel DM, Wasserman TH, Hence M, et al: Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 18:3339-3345, 2000
56. Milas L, Kishi K, Hunter N, et al: Enhancement of tumor response to gamma-radiation by an inhibitor of cyclooxygenase-2 enzyme. J Natl Cancer Inst 91:1501-1504, 1999
57. Huang SM, Harari PM: Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: Inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res 6:2166-2174, 2000